8-K: Mirum Pharma's LIVMARLI Succeeds in Phase 3 Liver Disease Study

Mirum Pharmaceuticals announced positive topline results from its Phase 3 EXPAND study for LIVMARLI, meeting all primary and secondary endpoints in treating ultra-rare cholestatic liver diseases.

Summary

• Mirum Pharmaceuticals announced positive topline results from the Phase 3 EXPAND study for LIVMARLI (maralixibat) in ultra-rare cholestatic liver diseases.
• The study met its primary endpoint for reducing pruritus in pediatric patients and achieved statistical significance across all five prespecified secondary endpoints.
• In the primary analysis population of pediatric patients, maralixibat showed a statistically significant improvement in pruritus compared to placebo, with a mean 1.81-point reduction in ItchRO(Obs) severity score versus 0.83 for placebo.
• Maralixibat also demonstrated a significant reduction in serum bile acids (sBA), with a 70.1% decrease from baseline compared to 3.5% for placebo.
• Safety findings were consistent with prior clinical experience, with no new safety signals identified.
• The company plans to submit a supplemental New Drug Application in the U.S. in the first half of 2027 based on these results.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, with the Phase 3 study meeting all primary and secondary endpoints, indicating strong efficacy for LIVMARLI in treating ultra-rare cholestatic liver diseases.

Positives

• The Phase 3 EXPAND study met its primary endpoint, demonstrating a statistically significant improvement in pruritus in pediatric patients with ultra-rare cholestatic liver diseases.
• All five prespecified secondary endpoints were also met with statistical significance, including those in the critical biliary atresia (BA) with a native liver subgroup.
• Maralixibat showed a substantial reduction in serum bile acids (sBA) by 70.1% compared to 3.5% for placebo.
• Safety profile of maralixibat was consistent with previous studies, with no new safety signals observed.
• The addressable patient population for Livmarli in Alagille syndrome (ALGS) is estimated at 2,000 pediatric patients, representing a market opportunity greater than $500.0 million.
• Significant addressable patient populations also exist for progressive familial intrahepatic cholestasis (PFIC) and biliary atresia (BA).

Negatives

• While generally consistent, treatment-emergent adverse events (TEAEs) were high in both groups (96.0% for maralixibat, 96.3% for placebo).
• Diarrhea was a notable adverse event, occurring in 64.0% of patients treated with maralixibat compared to 11.1% in the placebo group.
• Serious adverse events (SAEs) were reported in 20.0% of maralixibat-treated patients and 18.5% of placebo-treated patients.

Risks

• Actual results may differ from forward-looking statements due to risks and uncertainties associated with pharmaceutical product development.
• The company faces risks inherent in its business, as detailed in other SEC filings.
• Undue reliance on forward-looking statements is cautioned, as they speak only as of the date of the report.

Future Outlook

Mirum Pharmaceuticals plans to submit a supplemental New Drug Application in the United States in the first half of 2027 based on the positive Phase 3 EXPAND study results. The company also estimates significant market opportunities for Livmarli in various ultra-rare cholestatic liver diseases.

Management Comments

• The Company believes the prevalent patient population in the United States and Europe for Livmarli for cholestatic pruritus in patients with Alagille syndrome (ALGS) is approximately 4,000 5,500 pediatric ALGS patients, and of that prevalent population, approximately 2,000 pediatric ALGS patients are addressable, which, based on the Companys current expectations and beliefs, represents a greater than $500.0 million market opportunity.
• The Company believes the addressable patient population in the United States and Europe for Livmarli for cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) is approximately 1,000 pediatric PFIC patients and more than 4,000 adult PFIC patients.
• The Company believes the addressable patient population in the United States and Europe for Livmarli for BA is approximately 2,000 BA patients.
• The Company estimates that approximately 300 patients have been diagnosed in the United States with fibrodysplasia ossificans progressiva (FOP) and that the prevalent patient population worldwide is approximately 900 FOP patients.

Industry Context

StockSavvy.ai notes that the successful completion of this Phase 3 study for LIVMARLI in ultra-rare cholestatic liver diseases is a significant milestone for Mirum Pharmaceuticals and aligns with the industry trend of developing targeted therapies for underserved patient populations with high unmet needs.

Stakeholder Impact

• Shareholders: Positive impact expected due to successful clinical trial results, potentially leading to regulatory approval and market expansion.
• Patients: Potential for improved treatment outcomes and quality of life for individuals suffering from ultra-rare cholestatic liver diseases.
• Healthcare Providers: Availability of a new therapeutic option for managing complex liver conditions.

Next Steps

• Submit a supplemental New Drug Application in the United States in the first half of 2027.

Key Dates

Recommendation

The strong positive results from the Phase 3 EXPAND study, meeting all key efficacy endpoints with a favorable safety profile, position LIVMARLI for potential regulatory approval and significant market penetration in a niche but important therapeutic area. This success significantly de-risks the asset and points towards substantial future revenue potential.

Keywords

LIVMARLI, maralixibat, cholestatic liver diseases, biliary atresia, pruritus, Phase 3 study, EXPAND study, serum bile acids